Hemostemix Inc. (HMTXF)

0.0400 0.0000 (0.00%) At close: 03:19PM EDT

Hemostemix Inc.

707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Canada

https://hemostemix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas A. Smeenk B.A., BA Hons	Co-Founder, President, CEO & Director	224.82k	N/A	1962
Ms. Christina Wu CPA	Interim Chief Financial Officer	47.72k	N/A	N/A
Mr. Peter Pavlin	Vice President of Operations	N/A	N/A	N/A
Dr. Fraser C. Henderson Sr., M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Corporate governance

Hemostemix Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.